CHEMICON International, Inc. (SERO) Licenses Its Patented Amplifluor Technology For Cancer Diagnostics To OncoMethylome Sciences S.A.
10/19/2005 5:13:10 PM
ATLANTA--(BUSINESS WIRE)--March 30, 2005--Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary and OncoMethylome Sciences S.A.("OMS") have entered into an agreement pursuant to which OMS has licensed Chemicon's patented fluorescent detection technology, Amplifluor(R), for the clinical development of diagnostic assays detecting DNA methylation patterns.
DNA methylation is one of the primary biological mechanisms that determine gene expression. Thus, DNA methylation is an essential control mechanism for the normal development and cellular functioning of organisms. Abnormal DNA methylation, or hyper-methylation of DNA, incorrectly switches off critical genes, such as tumor suppressor genes or DNA repair genes, allowing cancers to develop and progress. DNA methylation patterns act as specific markers for disease and measuring the differences in DNA methylation patterns between healthy and diseased states provides a reliable and sensitive method for identifying disease and disease progression.
comments powered by